Goldman Sachs Maintains a 'Neutral' on Salix Pharmaceuticals (SLXP); Unexpected FDA Setback

Go back to Goldman Sachs Maintains a 'Neutral' on Salix Pharmaceuticals (SLXP); Unexpected FDA Setback